Spain Oncology Therapeutics Market Report 2022 to 2030

Spain Oncology Therapeutics Market Analysis

$ 3999

By 2030, the Spain Oncology Therapeutics Market is anticipated to reach a value of $6.2 Bn from $3.5 Bn in 2022, growing at a CAGR of 7.4% during 2022-30. The Oncology Therapeutics Market in Spain is dominated by a few domestic pharmaceutical companies such as PharmaMar, Grifols, and Oryzon Genomics. The Oncology Therapeutics Market in Spain is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Spain Oncology Therapeutics is increasing due to the rise in initiatives taken by the country's government.

ID: IN10ESPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Dr. Vishwa Modhia

Buy Now

Spain Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Spain Oncology Therapeutics Market will reach a value of $6.2 Bn from $3.5 Bn in 2022, growing at a CAGR of 7.4% during 2022-30.

Spain is a high-income developed country located in Southwestern Europe. The coastlines include the Bay of Biscay, the Mediterranean Sea, and the Northern Atlantic Ocean. Cancer is the second leading cause of mortality in Spain, trailing only cardiovascular illness. However, everything points to cancer seizing the lead in the near future. According to the International Agency for Research on Cancer, the number of new cancer cases in Spain in 2020 was 282421. In 2020, the number of cancer deaths in Spain was 113054.

The risk of developing cancer before the age of 75 is 27.7%. The SNS's fundamental ideals are "universal," "equal," and "free." Most of the cancer care is delivered in large university hospitals that are owned and funded by the government. Spain’s government spent 10.7 % of its GDP on healthcare in 2020.

Spain Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The rising number of cancer cases is mostly related to smoking, a practice that began to proliferate among Spanish women 20 years ago. In Spain, smoking is fairly common. One in every four Spaniards smokes cigarettes on a daily basis, and another 25% of the Spanish population is a former smoker. However, disease-related deaths have been steadily declining since 1995. This is most likely owing to an increase in early detection and improved therapies. Breast cancer and colon cancer screening programmes are well-established, while prostate cancer screening lags behind. In addition, new cancer drugs are being approved by the European Medicines Agency (EMA). In Spain, all EMA-approved cancer drug costs are reimbursed by the Spanish National Health System (SNS), although some local restrictions have been a matter of concern in recent times. These aspects could boost Spain Oncology Therapeutics Market.

Market Restraints

Smoking cessation (especially among adolescents and women), improved access to genetic screening, and reduced treatment inequities are all essential and pressing future challenges. Spain is very vulnerable to pandemic-risk industries. It has a skewed labour market and a high structural unemployment rate. These factors may deter new entrants into the Spain Oncology Therapeutics Market.

Competitive Landscape

Key Players

PharmaMar: PharmaMar is a Spanish biopharmaceutical company that specializes in the development of marine-based cancer therapeutics. The company is currently developing several innovative marine-derived anticancer drugs
Grifols: Grifols is a Spanish multinational pharmaceutical and life sciences company that develops and produces a range of cancer therapeutics, including plasma-derived products, immunoglobulins, and haematology products
Oryzon Genomics: Oryzon Genomics is a Spanish biotechnology company that specializes in the development of epigenetic cancer therapeutics. The company is currently developing several innovative epigenetic therapies for a range of cancer types
Almirall: Almirall is a Spanish pharmaceutical company that focuses on the development and production of a range of cancer therapeutics, including chemotherapy drugs, targeted therapies, and immunotherapies

Notable Recent Deals

November 2022: After a failed clinical trial, the United States has removed an innovative new cancer medication that had recently been integrated into Spain's health system. Following the failure of a recent clinical trial, the US Food and Drug Administration (FDA) has ordered British pharmaceutical giant GlaxoSmithKline (GLK) to suspend sales of the novel cancer medication Blenrep. The medicine was banned in the United States barely two months after it was approved in Spain for patients who experienced relapses after completing all available therapies for multiple myeloma.

July 2022: Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging oncological epigenetics to develop therapies in diseases with high unmet medical needs, announced the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a patient-led, non-profit organisation based in the United States focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to investigate Oryzon's HDAC6 inhibitors.

Healthcare Policies and Reimbursement Scenarios

Spain's citizens have access to cancer treatments through its national healthcare system. The nation's drug approval and regulation are handled by the Spanish Agency of Medicines and Medical Devices (AEMPS). The Spanish Public Health System (SNS)'s Pricing and Reimbursement (PR) is then established by the Inter-Ministerial Commission for the Pricing of Medicines (CIPM). Spain also has a special system for assessing and reimbursing innovative cancer treatments called the "Plan for Scientific and Technical Research and Innovation." This system allows patients with life-threatening or serious diseases, including cancer, to access treatments that have not yet been approved for use in Spain.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.